儿童手足口病患者行临床营养支持与人干扰素 α-2b 喷雾剂治疗的疗效

Objective To investigate the clinical efficacy of human interferon α-2b spray combined with individualized parenteral nutrition support in children with hand-foot-mouth disease (HFMD). Methods A total of 120 pediatric patients with HFMD admitted to our hospital’ s pediatric department from February 2023 to December 2024 were enrolled. According to the principle of random number table method, they were divided into a control group (treated with human interferon α-2b spray alone) and an experimental group (treated with human interferon α-2b spray combined with individualized parenteral nutrition support), with 60 cases in each group. Results The overall effective rate in the experimental group was 95.00%, which was significantly higher than that in the control group (83.33%) (P＜0.05). The time required for symptom relief in the experimental group was significantly shorter than that in the control group (P＜0.05). Additionally, the levels of interleukin-6 (IL-6), interleukin-4 (IL-4), white blood cell (WBC) and highsensitivityC-reactive protein (hs-CRP) in the experimental group were significantly lower than those in the control group. Furthermore, the levels of immunoglobulin G (IgG), immunoglobulin A (IgA) and total protein (TP) were significantly higher than those in the control group, and the differences were statistically significant (P＞0.05). During the treatment period and a 28-day follow-up, two drug-related adverse events (3.33%) occurred in each group, with no statistically significant difference between the groups (P＞0.05). All adverse events met the CTCAE 5.0 grade II criteria, and symptoms resolved within 48 hours after discontinuation of the medication. Conclusion The combination of human interferon α-2b spray and individualized parenteral nutrition support demonstrates significant improvements in clinical outcomes for children with HFMD, effectively shortens symptom relief time, inhibits inflammatory responses, and exhibits good safety.